Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

Completed

• Conditions: Melanoma
• Interventions: Other: Non-Interventional

• Registration Number: NCT03438279
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2015-06-23
• Primary Completion: 2017-12-28
• Study Completion: 2017-12-28
• Study First Submitted: 2018-01-31
• Status Verified: 2018-02
• Study First Submitted QC: 2018-02-16
• Last Update Submitted: 2018-02-16
• Study First Posted: 2018-02-19
• Last Update Posted: 2018-02-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Diagnosis of melanoma

Read More

Exclusion Criteria

• Age less than 18 years old

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
First-Line Ipilimumab	Non-Interventional	patients who received ipilimumab as their first-line treatment

Primary Outcome Measures

Name	Time	Method
Prognostic Model of Overall Survival (OS)	10 years	The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies.

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Boston, Massachusetts, United States